BIOMAT Database Logo BIOMAT Database Logo

Severe gastritis due to pembrolizumab treatment in a lung cancer patient. 2020

Noriko Hayama, and Hiroaki Ihara, and Yuichirou Honma, and Yukinari Itoigawa, and Kyoichi Kaira, and Mitsuhiro Fujii
Department of Respiratory Medicine Koto Hospital Tokyo Japan.

Immune checkpoint inhibitors (ICIs) are known to induce gastrointestinal adverse events. Colitis occurs most frequently, and gastritis is less common. A few case reports of gastritis induced by ICIs have indicated that colitis induced by cytotoxic T-lymphocyte antigen-4 (CTLA-4) resembles inflammatory bowel disease (IBD) and that programmed death-1/programmed death ligand-1 (PD-1/PD-L1) inhibitor can also induce the same type of colitis. We herein encountered a case of gastritis arising after 25 cycles of pembrolizumab administration in which the pathological and endoscopic findings resembled those of IBD. ICIs may induce gastritis in a manner similar to the pathogenesis of IBD.

UI MeSH Term Description Entries

Related Publications

Noriko Hayama, and Hiroaki Ihara, and Yuichirou Honma, and Yukinari Itoigawa, and Kyoichi Kaira, and Mitsuhiro Fujii
Severe pembrolizumab-induced gastritis in a patient with lung adenocarcinoma.
February 2022, Revista espanola de enfermedades digestivas,
Noriko Hayama, and Hiroaki Ihara, and Yuichirou Honma, and Yukinari Itoigawa, and Kyoichi Kaira, and Mitsuhiro Fujii
Severe cytomegalovirus gastritis due to pembrolizumab-induced agranulocytosis.
February 2024, Gastrointestinal endoscopy,
Noriko Hayama, and Hiroaki Ihara, and Yuichirou Honma, and Yukinari Itoigawa, and Kyoichi Kaira, and Mitsuhiro Fujii
Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient.
November 2022, Diagnostics (Basel, Switzerland),
Noriko Hayama, and Hiroaki Ihara, and Yuichirou Honma, and Yukinari Itoigawa, and Kyoichi Kaira, and Mitsuhiro Fujii
Severe cytomegalovirus gastritis after pembrolizumab in a patient with melanoma.
August 2020, Current oncology (Toronto, Ont.),
Noriko Hayama, and Hiroaki Ihara, and Yuichirou Honma, and Yukinari Itoigawa, and Kyoichi Kaira, and Mitsuhiro Fujii
Severe bullous pemphigoid in a metastatic lung cancer patient treated with pembrolizumab.
July 2019, The Journal of dermatology,
Noriko Hayama, and Hiroaki Ihara, and Yuichirou Honma, and Yukinari Itoigawa, and Kyoichi Kaira, and Mitsuhiro Fujii
Sepsis due to phlegmonous gastritis in a cancer patient.
March 2023, Revista espanola de enfermedades digestivas,
Noriko Hayama, and Hiroaki Ihara, and Yuichirou Honma, and Yukinari Itoigawa, and Kyoichi Kaira, and Mitsuhiro Fujii
Immune-mediated Gastritis in a Patient with metastatic Lung Cancer due to Therapy with the immune Checkpoint Inhibitor Pembrolizumab - Differences and Similarities in Comparison to "endogenous" autoimmune Type A Gastritis and a review of literature.
October 2023, Zeitschrift fur Gastroenterologie,
Noriko Hayama, and Hiroaki Ihara, and Yuichirou Honma, and Yukinari Itoigawa, and Kyoichi Kaira, and Mitsuhiro Fujii
Severe upper gastrointestinal disorders in pembrolizumab-treated non-small cell lung cancer patient.
August 2018, Respirology case reports,
Noriko Hayama, and Hiroaki Ihara, and Yuichirou Honma, and Yukinari Itoigawa, and Kyoichi Kaira, and Mitsuhiro Fujii
Severe polyradiculoneuritis associated with the combination of ipilimumab and pembrolizumab in a lung cancer patient.
January 2018, Neurology India,
Noriko Hayama, and Hiroaki Ihara, and Yuichirou Honma, and Yukinari Itoigawa, and Kyoichi Kaira, and Mitsuhiro Fujii
Development of Thyroid Carcinoma During Treatment With Pembrolizumab in a Lung Cancer Patient.
June 2020, The Annals of thoracic surgery,
Copied contents to your clipboard!